Recent Quotes (30 days)

You have no recent quotes
chg | %

Dechra Pharmaceuticals plc news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

DPH 1,378.00 +6.00 (0.44%)
price chart
Dechra Pharmaceuticals plc 12.5% Potential Upside Indicated by Cantor Fitzgerald
Dechra Pharmaceuticals plc using EPIC/TICKER code LON:DPH has had its stock rating noted as 'Reiterates' with the recommendation being set at 'BUY' this morning by analysts at Cantor Fitzgerald.
Cantor Fitzgerald Indicates Potential 13.29% Increase In Shares Of Dechra ...  Fiscal Standard
GW Pharmaceuticals PLC- ADR 51% Potential Upside Now Implied by Cantor ...  Cosumnes Connection (subscription)
Dechra Pharmaceuticals PLC: Annual Results
Dechra is an international specialist veterinary pharmaceuticals and related products business. Its expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide.
Is Dechra Pharmaceuticals plc a better buy than GlaxoSmithKline plc after ...  Motley Fool UK
Dechra Pharmaceuticals plc Still Leads GlaxoSmithKline plc, AstraZeneca plc ...  Investomania (blog)
Dechra Pharmaceuticals PLC: Australian Acquisition-Apex Laboratories for A$55m
Dechra is pleased to announce that it has agreed terms to acquire the business and assets of Apex Laboratories Pty Ltd ('Apex'), a privately owned veterinary pharmaceutical company which manufactures, markets and sells branded non-proprietary ...
Are RhythmOne plc, Dechra Pharmaceuticals plc and Pagegroup plc 'buys' after ...
Today's update from Pagegroup(LSE: PAGE) shows that the global recruitment company endured a somewhat mixed Q2. While its performance in southern Europe and Benelux was impressive with gross profit growth of 25% and 30% respectively, elsewhere ...
Dechra� Pharmaceuticals PLC: Trading Update & Notice of 2016 Annual Results  PR Newswire (press release)
A report released earlier today by numis about Dechra Pharmaceuticals(LON ...  Breaking Finance News
Dechra Pharmaceuticals PLC (LON:DPH) Receives 'Buy' Rating From Brokers At ...
Cantor Fitzgerald noted a target price of 1500 on Dechra Pharmaceuticals PLC's shares. According to this price target, it now means the analyst believes there is a potential increase of 13.38% from the company's current share price of 1323.
PREVIEW: Will Dechra Pharmaceuticals live up to heightened expectations?
Up around 15% in the past three months, veterinary drug maker Dechra Pharmaceuticals PLC (LON:DPH) will be a closely watched stock on Monday as it releases financial results for the full year.
Dechra Pharmaceuticals PLC, Agrees Acquisition of US-based Putney, Inc for ...
Dechra Pharmaceuticals PLC (LSE: symbol DPH) announces the conditional acquisition of the entire share capital of Putney, Inc, a leading developer of generic companion animal pharmaceuticals in the US, based in Portland, Maine.
Portland-based pet medicine company Putney acquired by British firm for $200 ...  Press Herald
Dechra Pharmaceuticals PLC: Half-Yearly Financial Report 2016
"All our business units are performing well, we are in the process of launching several new products, our international expansion plans are progressing as expected and we have made two strategic acquisitions.
Should you be buying AstraZeneca plc, Alliance Pharma plc and Dechra ...
One of the major concerns of investors in AstraZeneca (LSE: AZN) in recent years has been its ability to pay dividends. That's because it has been subjected to a patent cliff, where a number of key drugs have come off-patent and with the company ...
Should You Buy Dechra Pharmaceuticals plc, Enquest Plc & Cairn Energy PLC Today?
Pet medicines mammoth Dechra Pharmaceuticals (LSE: DPH) cheered the market with terrific half-year numbers in Monday business, propelling the stock 8% higher from the end of last week.